Is VACH or VIR more undervalued in 2026?

CirclFi compares Voyager Acquisition Corp (VACH) and Vir Biotechnology, Inc. (VIR) using 13 institutional-grade valuation models. VACH has a Quality of Company score of 3.9/10 while VIR scores 7.0/10.

Which is a better buy — VACH or VIR?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do VACH and VIR valuations compare?

VACH at $9.61 and VIR at $9.54 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

VACH vs VIR Valuation Comparison 2026 — Intrinsic Value Analysis

VACH

Biological Products, (No Diagnostic Substances)

Voyager Acquisition Corp

Quality

3.9

out of 10

Value Trap

—

Price

$9.61

Last close

Models

10/13

Active

VIR

Biological Products, (No Diagnostic Substances)

Vir Biotechnology, Inc.

Quality

7.0

out of 10

Value Trap

SAFE

Price

$9.54

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	VACH Fair Value	VACH Upside	VIR Fair Value	VIR Upside
Bayesian DCF	Intrinsic	$0.82	-91.5%	$2.47	-74.1%
Earnings Power Value	Intrinsic	—	—	$5.74	-42.6%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$3.84	-69.6%	$3.78	-60.4%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for VACH vs VIR — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

VACH vs VIR — Which Stock Is More Undervalued?

VIR scores higher with a 7.0/10 quality rating vs VACH's 3.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Voyager Acquisition Corp (VACH) and Vir Biotechnology, Inc. (VIR) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

VACH currently trades at $9.61 with a QOC of 3.9/10, while VIR trades at $9.54 with a QOC of 7.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).